| Literature DB >> 33755043 |
Nicole A Carnt1,2,3, Ignatius Pang4, Kathryn P Burdon5, Virginia Calder3, John K Dart3,6, Dinesh Subedi1,7, Alison J Hardcastle3.
Abstract
Purpose: Over a third of patients with Acanthamoeba keratitis (AK) experience severe inflammatory complications (SICs). This study aimed to determine if some contact lens (CL) wearers with AK were predisposed to SICs due to variations in key immune genes.Entities:
Year: 2021 PMID: 33755043 PMCID: PMC7991962 DOI: 10.1167/iovs.62.3.33
Source DB: PubMed Journal: Invest Ophthalmol Vis Sci ISSN: 0146-0404 Impact factor: 4.799
Distribution of Sample, Presenting History, and Clinical Features of Patients With and Without Severe Inflammatory Complications
| SICs | Non-SICs | ||
|---|---|---|---|
| Characteristics |
|
|
|
| Age at diagnosis, mean y ± SD ( | 38.3 ± 17.3 | 37.9 ± 16.2 | 0.906 |
| Sex, n (%) ( | |||
| M | 20 (50.0) | 30 (46.2) | 0.841 |
| F | 20 (50.0) | 35 (53.8) | |
| Topical corticosteroid use prior to AAT | |||
| No | 23 (67.6) | 52 (85.2) | 0.065 |
| Yes | 11 (32.4) | 9 (14.8) | |
| HSV keratitis treatment prior to AAT ( | |||
| No | 20 (58.8) | 48 (78.7) | 0.057 |
| Yes | 14 (41.2) | 13 (21.3) | |
| Bacterial keratitis treatment prior to AAT | |||
| No | 13 (38.2) | 25 (41.0) | 0.830 |
| Yes | 21 (61.8) | 36 (59.0) | |
| Patients referred to tertiary care (%) ( | |||
| No | 19 (47.5) | 37 (58.7) | 0.313 |
| Yes | 21 (52.5) | 26 (41.3) | |
| Disease stage at presentation | |||
| 1 | 5 (18.5) | 25 (43.9) | <0.001 |
| 2 | 9 (33.3) | 31 (54.4) | |
| 3 | 13 (48.1) | 1 (1.8) |
AAT = anti-amoebic therapy; HSV = herpes simplex virus.
Stage 1 corneal epitheliopathy; stage 2, stage 1 + epithelial defect, perineural infiltrate or stromal infiltrate; and stage 3, stage 2 + corneal ring infiltrate.
Allelic Frequencies of Targeted SNPs and Association Analysis in Patients With AK With Severe Inflammatory Complications (SICs) Compared to Those Without
| MAF (A1) | SICs vs. Non SICs Adjusted | ||||||
|---|---|---|---|---|---|---|---|
| Gene/Protein | SNP Reference | Chromosome: Base Pair (hg38 Assembly) | Alleles A2/A1 | SIC | Non-SIC | OR |
|
|
| rs1800872 | 1:206773062 | G/T | 0.175 | 0.285 | 0.595 | 0.192 |
| rs1800871 | 1:206773289 | G/A | 0.175 | 0.292 | 0.569 | 0.160 | |
| rs1800896 | 1:206773552 | T/C | 0.375 | 0.385 | 0.909 | 0.784 | |
| rs1800890 | 1:206776020 | A/T | 0.288 | 0.300 | 0.836 | 0.643 | |
|
| rs1884444 | 1:67168129 | G/T | 0.075 | 0.077 | 0.983 | 0.970 |
| rs7517847 | 1:67215986 | T/G | 0.450 | 0.346 | 2.035 | 0.073 | |
| rs2201841 | 1:67228519 | A/G | 0.263 | 0.323 | 0.884 | 0.742 | |
|
|
|
|
|
|
|
| |
| rs11465817 | 1:67255414 | C/A | 0.238 | 0.308 | 0.858 | 0.681 | |
| rs10889677 | 1:67259437 | C/A | 0.288 | 0.323 | 0.884 | 0.742 | |
|
| rs1143634 | 2:112832813 | G/A | 0.250 | 0.208 | 1.045 | 0.923 |
|
|
|
|
|
|
|
| |
|
| rs4073 | 4:73740307 | T/A | 0.413 | 0.508 | 0.508 | 0.0703 |
|
|
|
|
|
|
|
| |
| rs2227549 | 4:73741020 | A/G | 0.038 | 0.038 | 1.160 | 0.834 | |
| rs2227306 | 4:73741338 | C/T | 0.288 | 0.439 | 0.495 | 0.053 | |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
| rs3212227 | 5:159315942 | T/G | 0.125 | 0.231 | 0.554 | 0.200 |
| rs10045431 | 5:159387525 | C/A | 0.300 | 0.339 | 0.775 | 0.466 | |
| rs6887695 | 5:159395637 | G/C | 0.338 | 0.331 | 0.947 | 0.874 | |
|
| rs1800629 | 6:31575254 | G/A | 0.188 | 0.123 | 1.497 | 0.334 |
|
| rs2275913 | 6:52186235 | G/A | 0.300 | 0.377 | 0.842 | 0.588 |
| rs3748067 | 6:52190541 | C/T | 0.088 | 0.085 | 0.982 | 0.975 | |
|
| rs763780 | 6:52236941 | T/C | 0.050 | 0.031 | 2.330 | 0.279 |
| rs2397084 | 6:52237046 | T/C | 0.100 | 0.100 | 0.944 | 0.926 | |
|
| rs1800797 | 7:22726602 | G/A | 0.313 | 0.369 | 0.750 | 0.415 |
| rs1800796 | 7:22726627 | G/C | 0.113 | 0.108 | 1.074 | 0.886 | |
| rs1800795 | 7:22727026 | G/C | 0.313 | 0.369 | 0.846 | 0.629 | |
|
| rs1800972 | 8:6877901 | G/C | 0.175 | 0.246 | 0.701 | 0.395 |
| rs1799946 | 8:6877909 | C/T | 0.375 | 0.346 | 1.349 | 0.437 | |
| rs2702877 | 8:6878545 | C/G | 0.275 | 0.269 | 1.020 | 0.957 | |
| rs5743409 | 8:6879098 | C/A | 0.425 | 0.423 | 0.937 | 0.841 | |
|
| rs20576 | 8:23200707 | T/G | 0.175 | 0.185 | 1.253 | 0.605 |
| rs20575 | 8:23201811 | G/C | 0.375 | 0.485 | 0.739 | 0.346 | |
| rs6557634 | 8:23202743 | C/T | 0.363 | 0.477 | 0.711 | 0.284 | |
|
| rs10983755 | 9:117702392 | A/G | 0.038 | 0.015 | 4.065 | 0.282 |
| rs10759932 | 9:117702866 | T/C | 0.163 | 0.162 | 0.785 | 0.630 | |
| rs11536879 | 9:117709933 | A/G | 0.038 | 0.054 | 0.808 | 0.787 | |
| rs1927907 | 9:117710486 | C/T | 0.150 | 0.169 | 0.814 | 0.674 | |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
| rs11536889 | 9:117715853 | G/C | 0.163 | 0.162 | 0.780 | 0.593 | |
| rs7873784 | 9:117716658 | G/C | 0.175 | 0.169 | 1.412 | 0.403 | |
|
| rs187238 | 11:112164265 | C/G | 0.250 | 0.269 | 0.761 | 0.512 |
|
| rs2069718 | 12:68156382 | G/A | 0.425 | 0.369 | 1.302 | 0.445 |
| rs1861494 | 12:68157629 | T/C | 0.300 | 0.300 | 0.935 | 0.826 | |
| rs2430561 | 12:68158742 | T/A | 0.463 | 0.462 | 1.109 | 0.755 | |
|
|
|
|
|
|
|
|
|
| rs2227485 | 12:68253933 | A/G | 0.475 | 0.408 | 1.216 | 0.567 | |
| rs2227478 | 12:68254842 | A/G | 0.400 | 0.292 | 1.996 | 0.0665 | |
| rs2227473 | 12:68255258 | C/T | 0.113 | 0.131 | 1.243 | 0.666 | |
| rs2227472 | 12:68255353 | C/T | 0.463 | 0.415 | 1.174 | 0.634 | |
|
| rs4788084 | 16:28528527 | C/T | 0.375 | 0.323 | 1.294 | 0.423 |
|
| rs1800471 | 19:41352971 | C/G | 0.063 | 0.085 | 0.530 | 0.353 |
| rs1800469 | 19:41354391 | G/A | 0.313 | 0.277 | 1.178 | 0.666 | |
|
| rs4819554 | 22:17084145 | A/G | 0.238 | 0.192 | 1.428 | 0.387 |
| rs2229151 | 22:17108407 | G/A | 0.025 | 0.023 | 1.288 | 0.758 | |
Statistically significant differences in bold typeface.
MAF = minor allele frequency.
SICS versus age at diagnosis, sex, topical corticosteroid use prior to anti-amoebic therapy and HSV keratitis treatment prior to anti-amoebic therapy.
Genotype Frequencies of CXCL8 (Encodes IL-8) and TLR-4 in Patients With Severe Inflammatory Complications (SICs) and Controls
| Gene/Protein | SNPs | Genotypes | SICs (%) ( | Non-SICs (%) ( | Adjusted |
|---|---|---|---|---|---|
|
| rs2227543 C/T | TT | 3 (7.5) | 14 (21.5) | 0.0145 |
| TC | 15 (37.5) | 33 (50.8) | |||
| CC | 22 (55.0) | 18 (27.7) | |||
| rs1126647 A/T | TT | 2 (5.0) | 14 (21.5) | 0.0111 | |
| TA | 16 (40.0) | 32 (49.2) | |||
| AA | 22 (55.0) | 19 (29.2) | |||
|
| rs4986790 A/G | GG | 0 | 0 | 0.0541 |
| GA | 8 (20.0) | 4 (6.2) | |||
| AA | 32 (80.0) | 61 (93.8) | |||
| rs4986791 C/T | TT | 0 | 0 | 0.0290 | |
| TC | 9 (22.5) | 4 (6.2) | |||
| CC | 31 (77.5) | 61 (93.8) |
Figure.Linkage disequilibrium structure of selected SNPs in regions of interest in CXCL8 (encodes IL-8) (A) and TLR-4 (B). LD blocks were created with the default algorithm in HaploView program (version 4.1) that creates 95% confidence bounds on the normalized coefficient of linkage disequilibrium (D′) considered being in strong LD where 95% of the comparisons made are informative. The coloring of the boxes depends on two scores, the logarithm of the odds (LOD) and D′, high association (LOD > = 2 and D′ = 1, red), low association (LOD < 2 and D′ = 1, blue), and no association (LOD < 2 and D′ < 1, white). LOD score are shown within the box if D′ < 1.